A study from Scripps Clinic physicians suggests that patients taking GLP-1 weight loss medications may be able to maintain their weight loss with reduced dose frequency, challenging the current standard of weekly injections. The findings, published in the medical journal Obesity, could address concerns about long-term medication use and out-of-pocket costs for patients.
Study Details and Results
Scripps Clinic obesity specialist Mitch Biermann, M.D., Ph.D., and internal medicine resident Michelle Wong, M.D., conducted a retrospective case study of 30 patients who reduced their GLP-1 dose frequency for an average of 36 weeks. Twenty-one participants took tirzepatide and nine took semaglutide. Most participants sustained their peak weight loss even after reducing doses to once every two weeks or, for some, as infrequently as once every six weeks. Weight-related metabolic measurements including blood pressure, triglycerides, HDL cholesterol, and HbA1c either held steady at their best levels or improved. While on reduced dose frequency, patients on average experienced a slight additional loss of weight. Average HbA1c and blood pressure remained unchanged, triglycerides improved slightly, and HDL levels improved significantly.
Current Barriers and Clinical Implications
“The current GLP-1 standard of care gets a patient to their maximum amount of weight loss, but once that plateau is reached, there is no protocol for an appropriate reduced dose schedule to maintain that result or even to wean them off the medication,” Dr. Biermann said. Individual weekly doses can cost hundreds of dollars, and many people pay out-of-pocket because health insurance plans typically don’t cover these medications. The option to reduce dose frequency could lower costs while decreasing overall medication burden.
Study Limitations and Future Research
Four patients withdrew from the study and returned to standard weekly dosing after gaining weight. Researchers acknowledged several limitations, including potential selection bias, lack of blinding, and the possibility of placebo effects. The team noted that larger randomized controlled trials are needed to confirm findings and may help address concerns about indefinite therapy, lower health care costs, ease supply constraints, and broaden access to GLP-1 medications.
Dr. Biermann clarified that the dosing frequency studied differs from microdosing, a practice promoted on social media, emphasizing that medications should be taken as prescribed by physicians and per FDA guidelines.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://menafn.com/1110789680/New-Study-Shows-Scripps-Patients-Maintained-Weight-Loss-After-Reducing-GLP-1-Treatment-Frequency